



December 17, 2024

To,

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Symbol: NIDAN

Ref: your email dated 13.12.2024 regarding clarification for Financial Results – Nidan.

Subject: Clarification Letter.

Dear Sir/Ma'am,

This is with reference to your email dated 13.12.2024 regarding clarification for financial results of the Company submitted on 14th November, 2024. We wish to clarify that the said results have been signed Ms. Tejal Anil Jayakar (DIN:07984686) who is the Executive Director and CFO of the Company and therefore Ms. Tejal Anil Jayakar is authorised to sign the said results.

In Financial results which we have submitted on 14th November, 2024, We have mentioned her designation as 'Director & CFO' and now as per directions of your good offices, We are submitting the same results with her designation as 'Executive Director & CFO'.

Please note that there are no changes in results apart from her designation.

We hope that above information is in line with your requirement.

Thanking You,

Yours Sincerely,

For Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686



Nidan Laboratories And Healthcare Limited
CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (W), 401303
Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in
Statement of Unaudited Financial Results for the half year Ended as on 30th September 2024.

	Particulars	Half Year ended (Rs in lakhs)			Year Ended
		30-Sep-24	30-Sep-23	31-Mar-24	31-Mar-24
		UnAudited	Unaudited	Audited	Audited
1	Income				
	a) Revenue from Operations	1,053.27	1,182.44	1,235.30	2,417.74
	b) Other Income	103.09	152.30	122.34	274.64
	Total Income (a+b)	1,156.36	1,334.74	1,357.64	2,692.38
2	Expenses				
	a) Cost of Materials Consumed	47.99	47.40	47.60	95.00
	b) Changes in inventories of Finished Goods, Work in Progress and Stock-in-Trade	(0.79)	16.15	(9.82)	6.33
	c) Employee benefit expenses	183.82	227.95	232.33	460.28
	d) Finance Costs	87.93	97.69	120.37	218.06
	e) Depreciation and Amortization expenses	133.55	127.52	159.08	286.60
	f) Other Expenses	562.48	557.85	653.86	1,211.72
	Total Expenses (a to f)	1,014.99	1,074.56	1,203.41	2,277.98
3	Profit before Exceptional and Extraordinary Items & Tax	141.37	260.18	154.23	414.40
4	Exceptional & Extraordinary Items	-	-	651.27	651.27
5	Profit before Tax and after exceptional & extraordinary item (3-4)	141.37	260.18	(497.04)	(236.87)
6	Tax Expenses				
	a) Current Tax	36.00	67.98	52.02	120.00
	b) Deferred Tax Asset/Liability	(4.75)	1.86	(35.51)	(33.65)
	c) Tax of earlier year	-	(1.90)	1.91	0.01
	Total tax expenses	31.25	67.94	18.43	86.37
7	Profit for the period / year	110.13	192.24	(515.47)	(323.24)
	Paid-up equity share capital				
8	(Face value of Rs 10/- per share)	1,390	1,390	1,390	1,390
	Earnings Per Share (not annualized)				
9	a) Basic EPS	0.79	1.38	-3.71	-2.33
	b) Diluted EPS	0.79	1.38	(3.71)	(2.33)

Notes:

- 1) The above Financial Results are reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on 14th November 2024.
- 2) The equity shares of the company are listed on SME Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure requirements) Regulations, 2009 and hence exempted from Compulsary adoption of Ind AS for the preparation of Financial statements vide Notification dated 16th February, 2015 issued by ministry of corporate affairs.
- 3) During the year the Company has done investment in one of the group company of Rs 2200 lakhs
- 4) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.
- 5) The figures of the corresponding previous half year have been regrouped/rearranged wherever considered necessary to make them comparable





For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

Tejal Anil Jayakar
Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 14th November 2024
Place : Virar

Nidan Laboratories And Healthcare Limited
Statement of Assets & Liabilities as at 30th September 2024

Rs in lakhs


	Particulars	30th September 2024 (UnAudited)	As at 31st March 2024 (Audited)
I	Equity & Liabilities		
	1. Shareholders' funds		
	Equity Share Capital	1,390.00	1,390.00
	Reserves and Surplus	5,340.73	5,230.61
		6,730.73	6,620.61
	2. Non - Current Liabilities		
	(a) Long - Term Borrowings	426.62	429.38
	(b) Other Long term liabilities	17.29	16.64
	(c) Long Term Provisions	56.47	56.47
		500.38	502.50
	3. Current Liabilities		
	(a) Short - Term Borrowings	749.89	814.08
	(b) Trade Payables		
	(i) Total outstanding due of micro enterprises and small enterprises	13.16	15.42
	(ii) Total outstanding dues of creditors other than micro enterprises and small enterprises	81.66	57.54
	(c) Other Current Liabilities	116.42	127.30
	(d) Short - Term Provisions	152.91	117.62
		1,114.04	1,131.97
	TOTAL	8,345.15	8,255.08
II	Assets		
	1. Non - Current Assets		
	(a) Property Plant & Equipment and Intangible Assets		
	(i) Property, Plant & Equipments	1,741.64	1,793.51
	(ii) Intangible Asset	1.51	1.71
	(ii) Capital workin progress	6.33	3.50
	(b) Non-Current Investments	2,000.00	-
	(c) Long - Term Loans and Advances	3,355.46	3,276.82
	(d) Deferred Tax Asset (Net)	86.71	81.95
	(e) Other Non Current Assets	70.72	69.82
		7,262.37	5,227.30
	2. Current Assets		
	(a) Inventories	30.99	30.19
	(b) Trade Receivables	50.16	52.44
	(c) Cash and Cash Equivalents	279.54	284.99
	(d) Short - Term Loans and Advances	335.71	2,396.25
	(e) Other Current Assets	386.38	263.91
		1,082.78	3,027.78
	TOTAL	8,345.15	8,255.08
		For and on behalf of Board of Directors Nidan Laboratories and Healthcare Limited	
		 Tejal Anil Jayakar Executive Director & CFO DIN:07984686	
Date : 14th November 2024 Place : Virar			

Nidan Laboratories And Healthcare Limited
Statement Of Cash Flows For The half year ended 30th September 2024

Particulars	Rs. in lakhs	
	Half Year ended 30th September 2024	Year ended 31st March 2024
<u>A - CASH FLOW FROM OPERATING ACTIVITIES</u>		
Profit Before Tax	141.37	(236.87)
Add/ (less) Adjustment for:		
Interest Income	(99.62)	(264.64)
Interest Expenses	85.90	199.17
Interest on income tax	-	9.38
Sundry Balance w/off	-	34.60
Depreciation on property plant & equipment	133.55	286.60
Loss on discard of Property plant & Equipment	-	115.10
Provision for Doubtful debts	-	536.17
(Gain)/loss on disposal of property, plant and equipment	(3.16)	2.89
Operating Profit Before Working Capital Changes	258.04	682.40
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	2.28	14.00
(Increase)/ decrease in Other Current Assets	(122.47)	(11.51)
(Increase) / decrease in Other Non current assets	(0.90)	2.49
(Increase) / decrease in Inventories	(0.79)	6.33
Increase / (decrease) in Trade payables	21.86	52.36
Increase / (decrease) in Long term liability	0.65	(0.10)
Increase / (decrease) in Other current Liability	(10.89)	73.51
Increase / (decrease) in Short Term Provision	(0.68)	1.25
Increase / (decrease) in Long term Provisions	-	11.24
Cash Generated from Operations	147.11	831.96
Add/ (less) : Direct taxes paid (net of refund received)	(0.05)	(279.98)
Net Cash Inflow / (outflow) from Operating Activities	147.06	551.98
<u>B - CASH FLOW FROM INVESTING ACTIVITIES</u>		
Acquisition of property, plant and equipment / intangible assets / Capital work in progress	(87.84)	(73.63)
Investment in group company	(2,000.00)	
Proceeds from sale of property, plant and equipment	6.67	9.58
(Increase) / Decrease in Long term loans and advances (net)	20.98	1,032.41
(Increase) / decrease in Short Term Loans and Advances	2,060.54	(2,044.56)
Interest received	-	15.96
Net cash inflow/(outflow) from Investing Activities	0.35	(1,060.24)
<u>C - CASH FLOW FROM FINANCING ACTIVITIES</u>		
Proceeds / (repayment) of borrowings (net)	(66.96)	148.58
Interest Expenses	(85.90)	(197.26)
Net Cash inflow/(outflow) from Financing Activities	(152.86)	(48.69)
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	(5.45)	(556.95)
Add: Cash and Cash Equivalents at the beginning of the year	284.99	841.94
Cash and Cash Equivalents at the end of the year	279.54	284.99

Cash and Cash Equivalents at the end of the year consists of cash in hand and Balances with Banks are as follows :

Particulars	As at	
	30th September 2024	31st March 2024
Cash on hand	272.50	261.82
Balances with Banks	7.04	23.17
Cash and Cash Equivalents	279.54	284.99



For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

(Signature)
Tejal Anil Jayakar
Executive Director & CFO
DIN: 07984686

Date : 14th November 2024
Place : Virar

Nidan Laboratories And Healthcare Limited

CIN - L33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,
Vartak Road, Virar (w), 401303

Tel No. +91 8975610000, E-Mail : cs@nidanhealthcare.co.in, Website : www.nidanhealthcare.co.in

Statement of Unaudited Financial Results for the half year Ended on 30th September 2024

S.No	Particulars	Half Year Ended 30th September 2024 (UnAudited)	Half Year Ended 30th September 2023 (Unaudited)	Half Year Ended 31st March 2024 (Audited)	Year Ended 31st March 2024 (Audited)
1	Total Income from Operations	1,053.27	1,182.44	1,235.30	2,417.74
2	Net Profit for the period / year (before tax, exceptional and/or extraordinary items)	141.37	260.18	154.23	414.40
3	Net Profit for the period / year before tax (after exceptional and/or extraordinary items)	141.37	260.18	(497.04)	(236.87)
4	Net Profit for the period / year after tax (after exceptional and/or extraordinary items)	110.13	192.24	(515.47)	(323.24)
5	Total Comprehensive income for the period /year [comprising Profit for the period / year (after tax) and other comprehensive Income (after tax)]	110.13	192.24	(515.47)	(323.24)
6	Paid up Equity Share Capital	1,390.00	1,390.00	1,390.00	1,390.00
7	Reserves (excluding revaluation reserve)	5,340.73	5,746.09	(515.48)	5,230.61
8	Earnings Per Share (of RS 10/-each) (not annualized)				
	Basic	0.79	1.38	-3.71	-2.33
	Diluted	0.79	1.38	-3.71	-2.33

1) The above is an extract of the detailed format of Annual Financial Results filed with National Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in

2) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

3) Figures of the previous period have been regrouped wherever necessary, to correspond with the figures of the current period.



For and on behalf of Board of Directors
Nidan Laboratories and Healthcare Limited

F. Drang
Tejal Anil Jayakar
Executive Director & CFO
DIN:07984686

Date : 14th November 2024

Place : Virar



R. K. CHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Office: 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West), Dist- Palghar : 401303.
Contact : 9766095540 / 9769132203, **E-mail :** ravindra_chapawat@rediffmail.com / info.chapawat@gmail.com

Limited Review Report on unaudited financial results of Nidan Laboratories & Healthcare Limited for the half year ended 30 September 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Nidan Laboratories & Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Nidan Laboratories & Healthcare Limited** ("the Company") for the Half Year ended 30th September 2024 being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 ("Listing Regulations").

2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R.K Chapawat & Co.
Chartered Accountants
Firm's Registration No. 101708W

KchPawar

Kamlesh Chapawat
Partner

M. No. 181441

UDIN: - 24181441BKGENAS729

Place: Virar

Date: 14th November 2024

